NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Disappointing quarterly results combined with rising geopolitical tensions Wednesday to pressure U.S. markets lower on Wednesday. On Wednesday, North Korean leader Kim Jong Un responded to President Trump's warning to North Korea with a potential threat of a missile strike against U.S. territory Guam, sending major defense stocks to new all-time highs. The Dow Jones Industrial Average declined 0.17 percent to close at 22,048.70, while the S&P 500 Index dipped 0.04 percent to close at 2,474.02. The NASDAQ Composite Index fell 0.28 percent to close at 6,352.33.
"Definitely the primary reason stocks are down is geopolitical tensions," said J.J. Kinahan, Chief Strategist at TD Ameritrade, in an interview, according to MarketWatch. "But that's coming off 10 days higher on the Dow and we're still at highs. As much as we'd like to see the market go straight up, there's got to be a day of reckoning."
RDI Initiates Coverage on:
Anthera Pharmaceuticals Inc.
DryShips Inc.'s stock jumped 23.78% Wednesday, to close the day at $1.77. The stock recorded a trading volume of 26,895,165 shares, which was above its three months average volume of 4,668,460 shares. In the last year DryShips Inc.'s shares have traded in a range of 0.98 - 799,680.00. The share price has gained 80.61% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $10.60 is below its 200-day moving average of $1,349.21. Shares of DryShips have fallen approximately 99.99 percent year-to-date.
Access RDI's DryShips Inc. Research Report at:
On Wednesday, shares in Anthera Pharmaceuticals Inc. recorded a trading volume of 1,632,918 shares, which was above the three months average volume of 256,534 shares. The stock ended the day 10.61% higher at 1.46. The share price has gained 21.67% from its 52 week low with a 52 week trading range of 1.20 - 28.40.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $1.62 is greater than its 200-day moving average of $1.10. Shares of Anthera Pharmaceuticals have fallen approximately 71.88 percent year-to-date.
Access RDI's Anthera Pharmaceuticals Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.